Last reviewed · How we verify
Escitalopram oxylate
Escitalopram oxalate selectively inhibits the reuptake of serotonin at the neuronal membrane, increasing serotonin availability in the synaptic cleft.
Escitalopram oxalate selectively inhibits the reuptake of serotonin at the neuronal membrane, increasing serotonin availability in the synaptic cleft. Used for Major depressive disorder, Generalized anxiety disorder.
At a glance
| Generic name | Escitalopram oxylate |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Target | Serotonin transporter (SERT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | Phase 3 |
Mechanism of action
As the active S-enantiomer of citalopram, escitalopram oxalate is a selective serotonin reuptake inhibitor (SSRI) that blocks the serotonin transporter (SERT), preventing the reabsorption of serotonin from the synapse. This increases serotonin concentration and enhances neurotransmission, which is thought to improve mood and reduce anxiety symptoms. The oxalate salt formulation provides improved bioavailability and stability compared to the racemic mixture.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
Common side effects
- Nausea
- Headache
- Insomnia
- Somnolence
- Sexual dysfunction
- Diarrhea
- Dry mouth
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Escitalopram oxylate CI brief — competitive landscape report
- Escitalopram oxylate updates RSS · CI watch RSS
- AstraZeneca portfolio CI